PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.

[1]  Frank McCormick,et al.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.

[2]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[3]  S. Schwartz,et al.  The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.

[4]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[5]  Xin Huang,et al.  Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.

[6]  A. Børresen-Dale,et al.  PIK3CA mutations in advanced ovarian carcinomas , 2005, Human mutation.

[7]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Wei Zhao,et al.  Mutations of PIK3CA in gastric adenocarcinoma , 2005, BMC Cancer.

[9]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[10]  A. Ashworth,et al.  Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. , 2004, Biochimica et biophysica acta.

[11]  William R Sellers,et al.  PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. , 2003, Cancer treatment and research.

[12]  M. Shigemori,et al.  Autocrine Signaling through Ras Regulates Cell Survival Activity in Human Glioma Cells: Potential Cross‐Talk between Ras and the Phosphatidylinositol 3‐Kinase‐Akt Pathway , 2002, Journal of neuropathology and experimental neurology.

[13]  C. Downes,et al.  PTEN: The down side of PI 3-kinase signalling. , 2002, Cellular signalling.

[14]  B. Bapat,et al.  Considerations when analyzing the methylation status of PTEN tumor suppressor gene. , 2002, The American journal of pathology.

[15]  X. Matías-Guiu,et al.  CTNNB1 mutations and β-catenin expression in endometrial carcinomas , 2002 .

[16]  I. Pass,et al.  Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. , 2001, Biochemical Society transactions.

[17]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Kigawa,et al.  Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  X. Matías-Guiu,et al.  K‐ras mutations in endometrial carcinomas with microsatellite instability , 2001, The Journal of pathology.

[20]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.

[21]  J. Downward,et al.  Ras activation of phosphatidylinositol 3-kinase and Akt. , 2001, Methods in enzymology.

[22]  C. Eng,et al.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.

[23]  F. Haluska,et al.  Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. , 2000, Cancer research.

[24]  X. Matías-Guiu,et al.  PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. , 2000, Human pathology.

[25]  W. Sellers,et al.  The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. , 2000, Biochimica et biophysica acta.

[26]  L. Schriml,et al.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.

[27]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.

[28]  X. Matías-Guiu,et al.  Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. , 1998, Human pathology.

[29]  R. Levine,et al.  PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. , 1998, Cancer research.

[30]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[31]  A. Sakurada,et al.  PTEN1 is frequently mutated in primary endometrial carcinomas , 1997, Nature Genetics.

[32]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[33]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[34]  S. Sato,et al.  Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. , 1996, British Journal of Cancer.

[35]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Weissenbach,et al.  Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.

[37]  R. McLendon,et al.  Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. , 1995, Oncogene.

[38]  P. Goodfellow,et al.  Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. , 1995, Cancer research.

[39]  L. Cantley,et al.  Purification and characterization of phosphoinositide 3-kinase from rat liver. , 1990, The Journal of biological chemistry.